Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $4.80.

Several research analysts have recently issued reports on KPTI shares. Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. StockNews.com raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th.

Karyopharm Therapeutics Trading Down 1.4 %

Shares of Karyopharm Therapeutics stock opened at $0.77 on Friday. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The firm’s 50 day simple moving average is $0.89 and its two-hundred day simple moving average is $1.09. The firm has a market capitalization of $96.05 million, a price-to-earnings ratio of -0.61 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.09. The firm had revenue of $42.79 million during the quarter, compared to analyst estimates of $36.07 million. On average, sell-side analysts predict that Karyopharm Therapeutics will post -1.16 EPS for the current fiscal year.

Insider Transactions at Karyopharm Therapeutics

In other news, Director Deepika Pakianathan sold 231,548 shares of Karyopharm Therapeutics stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $0.95, for a total transaction of $219,970.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 1,074,687 shares of company stock valued at $1,043,723 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its position in Karyopharm Therapeutics by 6.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after purchasing an additional 108,286 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after buying an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at approximately $494,000. Ikarian Capital LLC grew its stake in Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after acquiring an additional 9,355 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth $339,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).